GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

The market for biopharmaceutical contract manufacturing reached $2.1B in 2006, and is forecasted to continue on its growth trajectory through 2008, according to a study published by HighTech Business Decisions ("Biopharmaceutical Contract Manufacturing 2007: Quality, Capacities and Emerging Technologies"). The company lists over 100 contract manufacturing provider companies on its website.



This week's podcast focuses on how a university-based contract manufacturing organization can compete in this market. Dr. Michael Meagher, who directs the University of Nebraska-Lincoln Biological Process Development Facility, addresses this issue during the podcast. Dr. Meagher talks about why he believes there is a need for university-based contract manufacturing organizations and how they vie for business along with their industrial counterparts. He takes us on a tour of his facility, describing the types of equipment and instrumentation available and the range of services offered.



Dr. Meagher also discusses how a university-based CMO differs from a contract manufacturing company and provides details on a typical client as well as the most common types of projects taken on by his facility.


Listen to this important and informative discussion then return to the blog to give your thoughts on the following question:


What are the main issues you would consider when trying to determine if you will use the services of a university-based contract manufacturing organization or a contract manufacturing-dedicated company?


Or, if you prefer, post your own topic on the biotech industry subject of your choice. Please share your opinions and observations.




Dr. Meagher graduated with a Ph.D. in Chemical Engineering from Iowa State University in 1987 and worked for Hoffmann La-Roche (Nutley, NJ) from 1987 to 1989 in downstream processing of recombinant proteins. Dr. Meagher accepted a position in June 1989 as an Assistant Professor in the Department of Food Science and Technology at the University of Nebraska-Lincoln and in 2000 joined the Department of Chemical and Biomolecular Engineering at UNL and is currently the Donald F. and Mildred T. Othmer Distinguished Professor of Chemical Engineering. The Biological Process Development Facility (BPDF) (http://bpdf.unl.edu), originally called the UNL Fermentation Facility (300 ft2 laboratory and 660 ft2 non-GMP pilot plant), was founded by Dr. Meagher in 1990. In January 2000, the BPDF moved into Othmer Hall, a new facility that is home to the BPDF, the Department of Chemical and Biomolecular Engineering, and the office for the Dean of the College of Engineering. The BPDF occupies 24,000 ft2 of Othmer Hall. Over the last 17 years the BPDF has grown from a 2 person operation focused on fermentation research into a multidisciplinary “turn-key” facility with over 43 full-time scientists, engineers, and administrative personnel focused on biopharmaceutical process research, development, and manufacturing of candidate vaccines and bio-therapeutics derived from recombinant expression systems. The BPDF is committed to advancing biopharmaceuticals derived from basic research into clinical trials. The BPDF has worked with over 30 different companies and government agencies on 35 different biotherapeutic proteins over the last 12 years. Dr. Meagher has published over 55 manuscripts, 6 book chapters, and 5 patents in fermentation and downstream processing and has generated over $33 million in funding.


Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?